A new publication involving cetrorelix appeared on June 30, 2026. The paper, titled "Evaluating progestin-primed and GnRH antagonist ovarian stimulation protocols in PGT-A cycles: implications for clinical practice," was published in BMC Pregnancy and Childbirth.
The publication addresses ovarian stimulation protocols used in cycles involving preimplantation genetic testing for aneuploidy (PGT-A), comparing progestin-primed approaches with GnRH antagonist protocols. Cetrorelix is referenced in the context of GnRH antagonist based ovarian stimulation.
No specific findings, outcomes, or efficacy data from this publication have been provided beyond its title and journal placement. This brief reports only the existence and bibliographic details of the publication as listed.
Readers interested in the broader context of cetrorelix, including its approved regulatory status and general use in reproductive medicine, can consult the compound overview for additional background.